NCT05501379

Brief Summary

Physical activity is an important aspect of cancer therapy but correct measurement of physical activity is difficult. In this study, the physical activity of patients undergoing cancer therapy is assessed by questionnaire and by motion tracker. The results are then compared to answer whether there are differences between the two measurements. Findings of this study will help to improve the assessment of physical activity in cancer patients.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Sep 2022

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 11, 2022

Completed
4 days until next milestone

First Posted

Study publicly available on registry

August 15, 2022

Completed
1 month until next milestone

Study Start

First participant enrolled

September 21, 2022

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2024

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 31, 2025

Completed
Last Updated

December 27, 2024

Status Verified

December 1, 2024

Enrollment Period

2.3 years

First QC Date

August 11, 2022

Last Update Submit

December 23, 2024

Conditions

LymphomaPancreas CancerColorectal Cancer

Keywords

Physical ActivityAccelerometerInternational Physical Activity QuestionnaireCancer TherapyGeneActivQuality of LifeFatigue

Outcome Measures

Primary Outcomes (1)

  • Comparison of physical activity assessments within 1 week after initiation of cancer therapy

    Difference in physical activity measured by the GeneActiv accelerometer and the short version of the International Physical Activity Questionnaire (IPAQ-sf) in metabolic equivalents of tasks (METs)

    1 week after initiation of cancer therapy

Secondary Outcomes (28)

  • Comparison of physical activity assessments 12 weeks after initiation of cancer therapy

    12 weeks after initiation of cancer therapy

  • Comparison of changes in physical activity between assessements within 1 week and 12 weeks after initiation of cancer therapy

    12 weeks after initiation of cancer therapy

  • Physical activity assessed by accelerometer

    1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy

  • Physical activity assessed by questionnaire

    1 week before initiation of cancer therapy, 1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy

  • Relation of Eastern Co-operative Oncology Group (ECOG) Performance Status to physical activity assessed by accelerometer

    1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy

  • +23 more secondary outcomes

Study Arms (1)

Cancer Patients

Patients with a verified diagnosis of lymphoma, colorectal or pancreatic cancer requiring surgical, chemo or radio therapy.

Other: No intervention - observational study only

Interventions

No intervention - observational study onlyOTHER

No intervention - observational study only

Cancer Patients

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients will be recruited at University Medicine Greifswald (Northeast Germany). Patients with the verified diagnosis of lymphoma, colerectal or pancreatic cancer requiring surgical, chemo or radio therapy will be identified in the respective wards or day care units of the hosptial.

You may qualify if:

  • verified diagnosis of lymphoma, colorectal or pancreatic cancer
  • requirement of surgical, chemo or radio therapy
  • provision of informed consent

You may not qualify if:

  • pregnancy
  • inability to provide consent
  • use of a rollator

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Medicine Greifswald

Greifswald, 17475, Germany

RECRUITING

MeSH Terms

Conditions

LymphomaPancreatic NeoplasmsColorectal NeoplasmsMotor ActivityFatigue

Condition Hierarchy (Ancestors)

Neoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System DiseasesDigestive System NeoplasmsNeoplasms by SiteEndocrine Gland NeoplasmsDigestive System DiseasesPancreatic DiseasesEndocrine System DiseasesIntestinal NeoplasmsGastrointestinal NeoplasmsGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal DiseasesBehaviorSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Ali A Aghdassi, Professor

    University Medicine Greifswald

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Ali A Aghdassi, Professor

CONTACT

+493834867230ali.aghdassi@med.uni-greifswald.de

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 11, 2022

First Posted

August 15, 2022

Study Start

September 21, 2022

Primary Completion

December 31, 2024

Study Completion

March 31, 2025

Last Updated

December 27, 2024

Record last verified: 2024-12

Locations

DE(1)